1-4 of 4
Amy DeZern
Close
Sort by
Journal Articles

Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study

Clinical Trials & Observations
Gregory A. Abel, Donnie Hebert, Cecilia Lee, Dana Rollison, Nancy Gillis, Rami Komrokji, James M. Foran, Jane Jijun Liu, Tareq Al Baghdadi, Joachim Deeg, Steven Gore, Wael Saber, Steffanie Wilson, Michael Otterstatter, Jason Thompson, Christine Borchert, Eric Padron, Amy DeZern, David Cella, Mikkael A. Sekeres
Journal: Blood Advances
Blood Adv (2023) 7 (14): 3506–3515.
https://doi.org/10.1182/bloodadvances.2022009000
Published: 2023
Includes: Supplemental data
Journal Articles

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2 -mutant myelodysplastic syndrome

Clinical Trials & Observations
Courtney D. DiNardo, Sangeetha Venugopal, Curtis Lachowiez, Koichi Takahashi, Sanam Loghavi, Guillermo Montalban-Bravo, Xuemei Wang, Hetty Carraway, Mikkael Sekeres, Ameenah Sukkur, Danielle Hammond, Kelly Chien, Abhishek Maiti, Lucia Masarova, Koji Sasaki, Yesid Alvarado, Tapan Kadia, Nicholas J. Short, Naval Daver, Gautam Borthakur, Farhad Ravandi, Hagop M. Kantarjian, Bhumika Patel, Amy Dezern, Gail Roboz, Guillermo Garcia-Manero
Journal: Blood Advances
Blood Adv (2023) 7 (11): 2378–2387.
https://doi.org/10.1182/bloodadvances.2022008378
Published: 2023
Includes: Supplemental data
Journal Articles

Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults

Clinical Trials & Observations
Heather J. Symons, Marianna Zahurak, Yilin Cao, Allen Chen, Kenneth Cooke, Christopher Gamper, Orly Klein, Nicolas Llosa, Elias T. Zambidis, Richard Ambinder, Javier Bolaños-Meade, Ivan Borrello, Robert Brodsky, Amy DeZern, Ivana Gojo, Margaret Showel, Lode Swinnen, B. Douglas Smith, Leo Luznik, Richard J. Jones, Ephraim J. Fuchs
Journal: Blood Advances
Blood Adv (2020) 4 (16): 3913–3925.
https://doi.org/10.1182/bloodadvances.2020001648
Published: 2020
Includes: Supplemental data
Journal Articles

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Clinical Trials & Observations
Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Koji Sasaki, Keyur Patel, Irene Ganan-Gomez, Elias Jabbour, Tapan Kadia, Farhad Ravandi, Courtney DiNardo, Gautham Borthakur, Koichi Takahashi, Marina Konopleva, Rami S. Komrokji, Amy DeZern, Teodora Kuzmanovic, Jaroslaw Maciejewski, Sherry Pierce, Simona Colla, Mikkael A. Sekeres, Hagop Kantarjian, Carlos Bueso-Ramos, Guillermo Garcia-Manero
Journal: Blood Advances
Blood Adv (2019) 3 (6): 922–933.
https://doi.org/10.1182/bloodadvances.2018026989
Published: 2019
Includes: Supplemental data